|
|
| www.smw.ch |
| Passweg J, Baldomero H, Chapuis B, Leibundgut K, Schanz U, Gratwohl A, for the STABMT Board. |
Swiss Med Wkly 2006;136:50-58
|
| Original article Peer reviewed article |
 |
| Summary Report from the Swiss Transplant Working Group for Blood and Marrow Transplantation (STABMT) Registry 1997–2003 In 1997, the Swiss Transplant Working Group Blood and Marrow Transplantation (STABMT) initiated a mandatory national registry for all haematopoietic stem cell transplants (HSCT) in Switzerland. As of 2003, information was collected of 2010 patients with a first HSCT (577 allogeneic (29%) and 1433 autologous (71%) HSCT) and 616 additional re-transplants. This included 1167 male and 843 female patients with a median age of 42.4 years (range 0.2–76.6 years). Main indications were leukaemias (592; 29%) lymphoproliferative disorders (1,061; 53%), solid tumours (295; 15%) and non-malignant disorders (62; 3%). At the time of analysis 1,263 patients were alive (63%), 747 had died (37%). Probability of survival, transplant related mortality or relapse at 5 years was 52%, 21%, 36% for allogeneic and 54%, 5%, 60% for autologous HSCT. Outcome depended on indication, donor type, stem cell source and age of patient. HSCT is an established therapy in Switzerland. These data describe current practice and outcome. |
Division of Haematology, University Hospital, Basel, Switzerland Division of Haematology, University Hospital, Geneva, Switzerland Division of Haematology/Oncology, Department of Paediatrics, University Hospital, Berne, Switzerland Division of Haematology, University Hospital, Zurich, Switzerland |
|
Copyright © 2006 EMH Swiss Medical Publishers Ltd. |
Top